Company: SVREW
Filing Date: 2025-01-31
Form Type: 424B5
Source: 0001213900-25-008656
Chunk: 39

Company: SaverOne 2014 Ltd.
Filing Date: 2025-01-31
Form: 424B5
Chunk 39
---
any applicable prospectus supplement, as well as the documents incorporated by reference or deemed incorporated by reference into this
prospectus, carefully before you invest in any securities. This prospectus may not be used to offer or sell securities unless accompanied by a prospectus supplement.

We may, from time to time,
offer to sell the securities, through public or private transactions, directly or through underwriters, agents or dealers, on or off
the Nasdaq Capital Market, or Nasdaq, at prevailing market prices or at privately negotiated prices. If any underwriters, agents or dealers
are involved in the sale of any of these securities, the applicable prospectus supplement will set forth the names of the underwriter,
agent or dealer and any applicable fees, commissions or discounts.

Our ADSs are listed on Nasdaq
under the symbol “SVRE”. On September 21, 2023, the closing price of our ADSs on Nasdaq was $0.78 per ADS. Our ordinary shares
also trade on the Tel Aviv Stock Exchange, or the TASE, under the symbol “SVRE”. On September 21, 2023, the last reported
sale price of our ordinary shares on the TASE was NIS 0.674 or $0.177 per share (based on the exchange rate reported by the Bank of Israel
on the same day).

The aggregate market value
of our outstanding voting and non-voting common equity held by non-affiliates on September 19, 2023, as calculated in accordance with
General Instruction I.B.5. of Form F-3, was approximately $3.9 million. We have not offered any securities pursuant to General Instruction
I.B.5 of Form F-3 during the prior 12 calendar month period that ends on and includes the date of this prospectus.

Investing in our securities involves a high degree of risk. Please carefully consider the risks discussed in this prospectus under “Risk Factors” beginning on page 4 and the “Risk Factors” in “Item 3: Key Information- Risk Factors” of our most recent Annual Report on Form 20-F incorporated by reference in this prospectus and in any applicable prospectus supplement for a discussion of the factors you should consider carefully before deciding to purchase these securities.

Neither the Securities and Exchange Commission, the Israel Securities Authority nor any state or other foreign securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a